[go: up one dir, main page]

MX2018005252A - Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica. - Google Patents

Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica.

Info

Publication number
MX2018005252A
MX2018005252A MX2018005252A MX2018005252A MX2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A
Authority
MX
Mexico
Prior art keywords
ovulation
treatment
hepatic steatosis
related oligo
steatosis related
Prior art date
Application number
MX2018005252A
Other languages
English (en)
Inventor
Ibáñez Lourdes
De Zegher Francis
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of MX2018005252A publication Critical patent/MX2018005252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un método y una composición para utilizarse en el tratamiento de una condición que se beneficie de la reducción de grasa hepática y/o visceral, tal como el síndrome de ovario poliquístico en niñas adolescentes o mujeres en edad fértil, que implica el uso de espironolactona, pioglitazona y metformina.
MX2018005252A 2015-10-27 2016-10-27 Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica. MX2018005252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (en) 2015-10-27 2016-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
MX2018005252A true MX2018005252A (es) 2018-09-18

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005252A MX2018005252A (es) 2015-10-27 2016-10-27 Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica.
MX2021007976A MX2021007976A (es) 2015-10-27 2018-04-26 Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007976A MX2021007976A (es) 2015-10-27 2018-04-26 Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.

Country Status (24)

Country Link
US (2) US20190060328A1 (es)
EP (2) EP3368044B1 (es)
JP (2) JP6999903B2 (es)
KR (1) KR102608158B1 (es)
CN (2) CN117379440A (es)
AR (1) AR106505A1 (es)
AU (1) AU2016344737C1 (es)
BR (1) BR112018008496A2 (es)
CA (1) CA3003076C (es)
DK (1) DK3368044T3 (es)
ES (1) ES2883282T3 (es)
GB (1) GB201518979D0 (es)
HU (1) HUE055778T2 (es)
IL (1) IL258876B (es)
LT (1) LT3368044T (es)
MA (2) MA43106B1 (es)
MX (2) MX2018005252A (es)
PL (1) PL3368044T3 (es)
RS (1) RS62764B1 (es)
RU (1) RU2745606C2 (es)
SI (1) SI3368044T1 (es)
TW (1) TWI791420B (es)
UY (1) UY36967A (es)
WO (1) WO2017072243A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200090927A (ko) 2017-12-19 2020-07-29 아카우오스, 인크. 내이에 대한 치료적 항체의 aav-매개 전달
EP3829546A1 (en) 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
EP3842803A1 (en) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 in polycystic ovary syndrome
EP4165195A2 (en) 2020-05-13 2023-04-19 Akouos, Inc. Compositions and methods for treating slc26a4-associated hearing loss
CR20230228A (es) 2020-12-01 2023-07-18 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
IL304006A (en) 2020-12-29 2023-08-01 Akouos Inc Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
EP4473011A1 (en) 2022-02-02 2024-12-11 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
CA2406871A1 (en) * 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (en) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
EP3829546A1 (en) * 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome

Also Published As

Publication number Publication date
RU2745606C2 (ru) 2021-03-29
CA3003076A1 (en) 2017-05-04
CA3003076C (en) 2023-12-05
AU2016344737A9 (en) 2018-08-09
CN117379440A (zh) 2024-01-12
AR106505A1 (es) 2018-01-24
MA54412A (fr) 2021-11-10
UY36967A (es) 2017-05-31
EP3368044A1 (en) 2018-09-05
PL3368044T3 (pl) 2021-12-20
WO2017072243A9 (en) 2018-07-26
IL258876B (en) 2022-03-01
JP2022009374A (ja) 2022-01-14
CN108778285A (zh) 2018-11-09
KR20180098234A (ko) 2018-09-03
LT3368044T (lt) 2021-10-25
AU2016344737C1 (en) 2021-10-07
RU2018119146A3 (es) 2020-02-25
MA43106A (fr) 2021-05-05
TW201720432A (zh) 2017-06-16
US20240000804A1 (en) 2024-01-04
DK3368044T3 (da) 2021-09-13
GB201518979D0 (en) 2015-12-09
EP3368044B1 (en) 2021-06-09
JP6999903B2 (ja) 2022-02-04
WO2017072243A8 (en) 2018-03-22
ES2883282T3 (es) 2021-12-07
WO2017072243A1 (en) 2017-05-04
SI3368044T1 (sl) 2022-05-31
RU2018119146A (ru) 2019-11-28
RS62764B1 (sr) 2022-01-31
MA43106B1 (fr) 2021-09-30
MX2021007976A (es) 2021-08-16
TWI791420B (zh) 2023-02-11
EP3892281A2 (en) 2021-10-13
EP3892281A3 (en) 2021-11-10
AU2016344737A1 (en) 2018-05-17
US20190060328A1 (en) 2019-02-28
KR102608158B1 (ko) 2023-11-29
AU2016344737B2 (en) 2021-07-08
BR112018008496A2 (pt) 2018-10-23
JP2019501113A (ja) 2019-01-17
IL258876A (en) 2018-06-28
HUE055778T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
MX2021007976A (es) Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.
HK1254358A1 (zh) 用於治療突觸核蛋白病的藥劑、用途和方法
IL273278A (en) Composition and method for treating autism
HK1248590A1 (zh) 用於治療貧血的組合物和方法
GB201919382D0 (en) Compositions and methods for preventing or treating muscle conditions
IL251215B (en) Cannabinoid preparation and method for treating pain
IL269637A (en) Preparations and methods for the treatment of synovial diseases
SG11202000866TA (en) Treatment agent composition for textile products
MX2021002851A (es) Reutilizacion de agente cloroso activado para el tratamiento de carne y aves.
IL269550A (en) Preparations and methods for treating diseases related to alpha-synuclein
HK1256541A1 (zh) 用於處理皮膚的方法和組合物
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
IL249640A0 (en) Preparations for the treatment of nosebleeds
HK1243635A1 (zh) 治療皮膚病況的組合物和方法
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
IL277463A (en) Vehicles and methods for treating itch
IL309770B2 (en) NK1 antagonist combination and method for treating synucleinopathies
PL3268347T3 (pl) Mieszaniny związków cheltujących i sposób wytwarzania takich mieszanin
ZA201904080B (en) Transalkylation process and catalyst composition used therein
PL3412784T3 (pl) Sposób obróbki wyrobów z nadstopów
IL260331A (en) Compounds and methods for the treatment of amyotrophic lateral sclerosis
IL279907A (en) Preparations and methods for treating stroke
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.
PL3325012T3 (pl) Kompozycja zawierająca cyneol do leczenia polipów nosa
PL3216452T3 (pl) Kompozycja do zapobiegania lub leczenia zapalenia błony śluzowej zawierająca jako skuteczny składnik NecroX